delta-like 1

Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is an IgG, κ inhibitor antibody derived from the American hamster, targeting mouse δ-like protein 1/DLL1.

Adintrevimab (ADG20) is a broad-spectrum neutralizing monoclonal antibody targeting SARS-CoV-2. It binds to a highly conserved epitope within the receptor-binding domain (RBD) of the spike glycoprotein, blocking its interaction with the ACE2 receptor. The Fc region is modified to extend its in vivo half-life. Research demonstrates potent neutralizing activity against various variants including Alpha, Beta, Gamma, and Delta, although its activity is significantly reduced against certain Omicron sub-lineages.

Tarlatamab (AMG-757) is a bispecific T cell engager (BiTE) antibody targeting DLL3 and CD3, with human DLL3 and CD3 KD = 0.64 nM/14.9 nM, for use in immuno-oncology therapy of small cell lung cancer (SCLC).

Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.